Chinese Medical Sciences Journal ›› 2021, Vol. 36 ›› Issue (3): 173-186.doi: 10.24920/003984

Special Issue: 人工智能与精准肿瘤学

• Review • Previous Articles     Next Articles

Multi-Omics and Its Clinical Application in Hepatocellular Carcinoma: Current Progress and Future Opportunities

Wanshui Yang1, Hanyu Jiang2, Chao Liu3, 4, Jingwei Wei5, 6, 7, Yu Zhou5, 6, 7, 8, Pengyun Gong3, 4, Bin Song2, *(), Jie Tian3, 4, 5, 6, 9, *()   

  1. 1Department of Nutrition, School of Public Health, Anhui Medical University, Hefei 230032, China
    2Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China
    3Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing 100191, China
    4Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing 100191, China
    5Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China
    6Beijing Key Laboratory of Molecular Imaging, Beijing 100190, China
    7University of Chinese Academy of Sciences, Beijing 100049, China
    8School of Life Science and Technology, Xidian University, Xi’an 710126, China
    9Engineering Research Center of Molecular and Neuro Imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi’an 710126, China
  • Received:2021-08-16 Accepted:2021-09-14 Published:2021-09-30 Online:2021-09-17
  • Contact: Bin Song,Jie Tian;
This review is structured in five parts including multi-omics in the clinical workflow of HCC, design and implementation of clinical cohort for HCC omics Study, methodology of radiomics, genomics and proteomics in HCC, and final summary of current limitation and future opportunities of multi-omics in HCC studies.

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the fourth leading cause of cancer related death worldwide. China covers over half of cases, leading HCC to be a vital threaten to public health. Despite advances in diagnosis and treatments, high recurrence rate remains a major obstacle in HCC management. Multi-omics currently facilitates surveillance, precise diagnosis, and personalized treatment decision making in clinical setting. Non-invasive radiomics utilizes preoperative radiological imaging to reflect subtle pixel-level pattern changes that correlate to specific clinical outcomes. Radiomics has been widely used in histopathological diagnosis prediction, treatment response evaluation, and prognosis prediction. High-throughput sequencing and gene expression profiling enabled genomics and proteomics to identify distinct transcriptomic subclasses and recurrent genetic alterations in HCC, which would reveal the complex multistep process of the pathophysiology. The accumulation of big medical data and the development of artificial intelligence techniques are providing new insights for our better understanding of the mechanism of HCC via multi-omics, and show potential to convert surgical/intervention treatment into an antitumorigenic one, which would greatly advance precision medicine in HCC management.

Key words: hepatocellular carcinoma, radiomics, proteomics, genomics, multi-omics

Copyright © 2021 Chinese Academy of Medical Sciences.  京公安备110402430088  京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health Commission of the People's Republic of China

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 


Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1